In accordance with the legislation of the Czech Republic, the Company provides services only to qualified investors!

Gracell Biotechnologies Inc. Financial results for the fourth quarter of 2020.

10.03.2021

GAAP net loss - $0.42, which is $0.32 worse compared to the previous year.
Cash and cash equivalents as of December 31, 2020 were $118.5 million.